metformin

metformin is a primary oral medication for managing type 2 diabetes mellitus and is also used for treating polycystic ovary syndrome. It belongs to the biguanide class of drugs and works primarily by decreasing glucose production in the liver and improving insulin sensitivity. First described in the scientific literature in the 1920s, its glucose-lowering properties were later elucidated through research led by Jean Sterne, leading to its widespread clinical adoption.

Medical uses

Its primary indication is the first-line pharmacological management of type 2 diabetes mellitus, often in conjunction with lifestyle modifications like diet and exercise. It is also prescribed for the management of polycystic ovary syndrome to address symptoms such as insulin resistance and anovulation. Beyond these core uses, it is investigated for potential roles in conditions like nonalcoholic fatty liver disease and as part of certain cancer treatment regimens, though these are not yet standard. The American Diabetes Association and other international bodies like the European Association for the Study of Diabetes include it in their major treatment guidelines.

Adverse effects

The most frequently reported issues involve the gastrointestinal tract, including diarrhea, nausea, and abdominal pain, which often subside with continued use. A rare but serious risk is lactic acidosis, a metabolic condition with high mortality, which is of particular concern in patients with significant kidney impairment or during events like sepsis. Long-term use has been associated with decreased absorption of vitamin B12, potentially leading to deficiency. Contraindications include severe renal failure, acute heart failure, and conditions predisposing to hypoxia, such as chronic obstructive pulmonary disease.

Pharmacology

Its main mechanism involves activation of the AMP-activated protein kinase pathway, leading to reduced hepatic gluconeogenesis. It decreases the production of glucose in the liver by inhibiting mitochondrial complex I and alters cellular energy metabolism. The drug is not metabolized by the cytochrome P450 system and is excreted unchanged by the kidneys, with a half-life of approximately 6 hours. It improves insulin sensitivity in peripheral tissues like muscle and adipose tissue, thereby enhancing glucose uptake.

History

The glucose-lowering effect of galega officinalis, a plant containing compounds related to it, was noted in medieval Europe. The related compound synthalin was used briefly in the 1920s before being withdrawn due to toxicity. French physician Jean Sterne pioneered clinical research on the compound in the 1950s, leading to its introduction for diabetes treatment in the United Kingdom in 1958 and later in Canada. The U.S. Food and Drug Administration approved it for use in the United States in 1994, after which it became one of the world's most prescribed medications.

Society and culture

It is on the World Health Organization's List of Essential Medicines and is widely available as a low-cost generic drug, increasing its accessibility globally. Notable brand names include Glucophage, originally marketed by the pharmaceutical company Merck Serono. Its potential off-label use for anti-aging and metabolic health has been popularized in communities like the Life Extension Foundation, though this remains controversial within mainstream endocrinology. Ongoing research into its repurposing is supported by major institutions like the National Institutes of Health and the American Federation for Aging Research.

Category:Antidiabetic drugs Category:World Health Organization essential medicines